1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Wu, Y.
Wang, J.
DeGrado, W.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C18 H23 N2 O S 1
315.453
(3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium
non-polymer
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
110
1315
1320
10.1073/pnas.1216526110
23302696
Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.
2013
10.2210/pdb2ly0/pdb
pdb_00002ly0
3497.116
Membrane ion channel M2
C19S
4
syn
polymer
315.453
(3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium
1
syn
non-polymer
no
no
SNDSSDPLVVAANIIGILHLILWILDRLFFK
SNDSSDPLVVAANIIGILHLILWILDRLFFK
A,B,C,D
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_database_status
pdbx_nmr_software
pdbx_nmr_spectrometer
struct_site
repository
Initial release
Database references
Database references
Data collection
Database references
Derived calculations
Other
1
0
2013-01-09
1
1
2013-01-23
1
2
2013-02-06
1
3
2023-06-14
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
_pdbx_nmr_software.name
_pdbx_nmr_spectrometer.model
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
BMRB
Y
RCSB
2012-09-10
REL
REL
REL
REL
A2Y
(3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium
221020
Influenza A virus
sample
AUTHORS STATE THAT THIS IS A DRUG-RESISTANT MUTANT.
structures with the lowest energy
100
20
2D 1H-15N HSQC
3D HNCO
3D HNCA
3D HNCACB
3D 1H-15N NOESY
3D 1H-13C NOESY
3D 1H-13C NOESY
3D 1H-13C NOESY
2D 1H-13C HSQC
3D CCH_TOCSY
2
mM
[U-100% 15N]
2
mM
[U-100% 13C; U-100% 15N]
2
mM
[U-100% 13C; U-100% 15N; U-80% 2H]
2
mM
[U-10% 13C; U-100% 15N]
2
mM
mixature of 50% 13C15N and 50% 12C14N
2
mM
13C15N of V27A30N31I33G34
0.05
6.8
ambient
313
K
simulated annealing
1
lowest energy
2 mM mM [U-100% 15N] protein, 90% H2O/10% D2O
90% H2O/10% D2O
2 mM mM [U-100% 13C; U-100% 15N] protein, 90% H2O/10% D2O
90% H2O/10% D2O
2 mM mM [U-100% 13C; U-100% 15N; U-80% 2H] protein, 90% H2O/10% D2O
90% H2O/10% D2O
2 mM mM [U-10% 13C; U-100% 15N] protein, 90% H2O/10% D2O
90% H2O/10% D2O
2mM mM mixature of 50% 13C15N and 50% 12C14N protein, 90% H2O/10% D2O
90% H2O/10% D2O
2mM mM 13C15N of V27A30N31I33G34 protein, 90% H2O/10% D2O
90% H2O/10% D2O
Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
processing
NMRPipe
Bartels et al.
chemical shift assignment
XEASY
Bartels et al.
peak picking
XEASY
Schwieters, Kuszewski, Tjandra and Clore
structure solution
X-PLOR NIH
Schwieters, Kuszewski, Tjandra and Clore
refinement
X-PLOR NIH
900
Bruker
AVANCE
Bruker Avance
800
Bruker
AVANCE
Bruker Avance
A2Y
100
2
A2Y
A2Y
100
A
SER
19
n
1
SER
19
A
ASN
20
n
2
ASN
20
A
ASP
21
n
3
ASP
21
A
SER
22
n
4
SER
22
A
SER
23
n
5
SER
23
A
ASP
24
n
6
ASP
24
A
PRO
25
n
7
PRO
25
A
LEU
26
n
8
LEU
26
A
VAL
27
n
9
VAL
27
A
VAL
28
n
10
VAL
28
A
ALA
29
n
11
ALA
29
A
ALA
30
n
12
ALA
30
A
ASN
31
n
13
ASN
31
A
ILE
32
n
14
ILE
32
A
ILE
33
n
15
ILE
33
A
GLY
34
n
16
GLY
34
A
ILE
35
n
17
ILE
35
A
LEU
36
n
18
LEU
36
A
HIS
37
n
19
HIS
37
A
LEU
38
n
20
LEU
38
A
ILE
39
n
21
ILE
39
A
LEU
40
n
22
LEU
40
A
TRP
41
n
23
TRP
41
A
ILE
42
n
24
ILE
42
A
LEU
43
n
25
LEU
43
A
ASP
44
n
26
ASP
44
A
ARG
45
n
27
ARG
45
A
LEU
46
n
28
LEU
46
A
PHE
47
n
29
PHE
47
A
PHE
48
n
30
PHE
48
A
LYS
49
n
31
LYS
49
A
SER
19
n
1
SER
19
B
ASN
20
n
2
ASN
20
B
ASP
21
n
3
ASP
21
B
SER
22
n
4
SER
22
B
SER
23
n
5
SER
23
B
ASP
24
n
6
ASP
24
B
PRO
25
n
7
PRO
25
B
LEU
26
n
8
LEU
26
B
VAL
27
n
9
VAL
27
B
VAL
28
n
10
VAL
28
B
ALA
29
n
11
ALA
29
B
ALA
30
n
12
ALA
30
B
ASN
31
n
13
ASN
31
B
ILE
32
n
14
ILE
32
B
ILE
33
n
15
ILE
33
B
GLY
34
n
16
GLY
34
B
ILE
35
n
17
ILE
35
B
LEU
36
n
18
LEU
36
B
HIS
37
n
19
HIS
37
B
LEU
38
n
20
LEU
38
B
ILE
39
n
21
ILE
39
B
LEU
40
n
22
LEU
40
B
TRP
41
n
23
TRP
41
B
ILE
42
n
24
ILE
42
B
LEU
43
n
25
LEU
43
B
ASP
44
n
26
ASP
44
B
ARG
45
n
27
ARG
45
B
LEU
46
n
28
LEU
46
B
PHE
47
n
29
PHE
47
B
PHE
48
n
30
PHE
48
B
LYS
49
n
31
LYS
49
B
SER
19
n
1
SER
19
C
ASN
20
n
2
ASN
20
C
ASP
21
n
3
ASP
21
C
SER
22
n
4
SER
22
C
SER
23
n
5
SER
23
C
ASP
24
n
6
ASP
24
C
PRO
25
n
7
PRO
25
C
LEU
26
n
8
LEU
26
C
VAL
27
n
9
VAL
27
C
VAL
28
n
10
VAL
28
C
ALA
29
n
11
ALA
29
C
ALA
30
n
12
ALA
30
C
ASN
31
n
13
ASN
31
C
ILE
32
n
14
ILE
32
C
ILE
33
n
15
ILE
33
C
GLY
34
n
16
GLY
34
C
ILE
35
n
17
ILE
35
C
LEU
36
n
18
LEU
36
C
HIS
37
n
19
HIS
37
C
LEU
38
n
20
LEU
38
C
ILE
39
n
21
ILE
39
C
LEU
40
n
22
LEU
40
C
TRP
41
n
23
TRP
41
C
ILE
42
n
24
ILE
42
C
LEU
43
n
25
LEU
43
C
ASP
44
n
26
ASP
44
C
ARG
45
n
27
ARG
45
C
LEU
46
n
28
LEU
46
C
PHE
47
n
29
PHE
47
C
PHE
48
n
30
PHE
48
C
LYS
49
n
31
LYS
49
C
SER
19
n
1
SER
19
D
ASN
20
n
2
ASN
20
D
ASP
21
n
3
ASP
21
D
SER
22
n
4
SER
22
D
SER
23
n
5
SER
23
D
ASP
24
n
6
ASP
24
D
PRO
25
n
7
PRO
25
D
LEU
26
n
8
LEU
26
D
VAL
27
n
9
VAL
27
D
VAL
28
n
10
VAL
28
D
ALA
29
n
11
ALA
29
D
ALA
30
n
12
ALA
30
D
ASN
31
n
13
ASN
31
D
ILE
32
n
14
ILE
32
D
ILE
33
n
15
ILE
33
D
GLY
34
n
16
GLY
34
D
ILE
35
n
17
ILE
35
D
LEU
36
n
18
LEU
36
D
HIS
37
n
19
HIS
37
D
LEU
38
n
20
LEU
38
D
ILE
39
n
21
ILE
39
D
LEU
40
n
22
LEU
40
D
TRP
41
n
23
TRP
41
D
ILE
42
n
24
ILE
42
D
LEU
43
n
25
LEU
43
D
ASP
44
n
26
ASP
44
D
ARG
45
n
27
ARG
45
D
LEU
46
n
28
LEU
46
D
PHE
47
n
29
PHE
47
D
PHE
48
n
30
PHE
48
D
LYS
49
n
31
LYS
49
D
author_defined_assembly
4
tetrameric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
PHE
48
-45.14
162.29
1
B
PHE
48
-45.19
162.38
1
C
PHE
48
-45.20
162.34
1
D
PHE
48
-45.29
162.37
5
A
PHE
47
-93.64
40.62
5
A
PHE
48
-45.84
173.82
5
B
PHE
47
-93.61
40.69
5
B
PHE
48
-45.85
173.82
5
C
PHE
47
-93.54
40.62
5
C
PHE
48
-46.01
173.81
5
D
PHE
47
-93.55
40.68
5
D
PHE
48
-46.06
173.93
6
A
PHE
47
-92.56
40.50
6
B
PHE
47
-92.58
40.55
6
C
PHE
47
-92.59
40.67
6
D
PHE
47
-92.72
40.68
7
A
PHE
48
-155.58
66.02
7
B
PHE
48
-155.69
66.46
7
C
PHE
48
-155.63
66.42
7
D
PHE
48
-155.52
66.54
8
A
SER
23
-149.12
-143.80
8
B
SER
23
-149.28
-143.76
8
C
SER
23
-149.18
-143.79
8
D
SER
23
-149.20
-143.75
9
A
PHE
47
-101.26
40.71
9
A
PHE
48
-45.71
86.47
9
B
PHE
47
-101.02
40.81
9
B
PHE
48
-45.83
86.58
9
C
PHE
47
-101.45
40.88
9
C
PHE
48
-45.81
86.21
9
D
PHE
47
-101.27
40.79
9
D
PHE
48
-45.92
86.47
11
A
ASP
24
-49.42
151.59
11
B
ASP
24
-49.40
151.25
11
C
ASP
24
-49.30
151.47
11
D
ASP
24
-49.79
151.04
13
A
PHE
47
-68.90
-72.41
13
B
PHE
47
-68.72
-72.52
13
C
PHE
47
-68.89
-72.45
13
D
PHE
47
-68.82
-72.44
15
A
SER
23
-75.89
-136.41
15
A
PHE
48
-155.16
83.55
15
B
SER
23
-76.00
-136.46
15
B
PHE
48
-155.09
83.54
15
C
SER
23
-75.81
-136.54
15
C
PHE
48
-155.10
83.51
15
D
SER
23
-75.86
-136.39
15
D
PHE
48
-155.06
83.69
18
A
PHE
48
-156.90
70.71
18
B
PHE
48
-156.89
70.92
18
C
PHE
48
-156.93
70.90
18
D
PHE
48
-156.84
70.76
19
A
SER
23
38.64
93.58
19
B
SER
23
38.52
93.66
19
C
SER
23
38.65
93.48
19
D
SER
23
38.55
93.73
Solution NMR structure of the influenza A virus S31N mutant (19-49) in presence of drug M2WJ332
1
N
N
1
N
N
1
N
N
1
N
N
2
N
N
A
ASP
24
A
ASP
6
HELX_P
A
PHE
47
A
PHE
29
1
1
24
B
ASP
24
B
ASP
6
HELX_P
B
PHE
47
B
PHE
29
1
2
24
C
ASP
24
C
ASP
6
HELX_P
C
PHE
47
C
PHE
29
1
3
24
D
ASP
24
D
ASP
6
HELX_P
D
PHE
47
D
PHE
29
1
4
24
VIRAL PROTEIN
influenza A virus, M2 channel, S31N inhibitor, VIRAL PROTEIN
Q6XT21_9INFA
UNP
1
19
Q6XT21
CNDSSDPLVVAANIIGILHLILWILDRLFFK
19
49
2LY0
19
49
Q6XT21
A
1
1
31
19
49
2LY0
19
49
Q6XT21
B
1
1
31
19
49
2LY0
19
49
Q6XT21
C
1
1
31
19
49
2LY0
19
49
Q6XT21
D
1
1
31
1
CYS
SEE REMARK 999
SER
19
2LY0
A
Q6XT21
UNP
19
1
2
CYS
SEE REMARK 999
SER
19
2LY0
B
Q6XT21
UNP
19
1
3
CYS
SEE REMARK 999
SER
19
2LY0
C
Q6XT21
UNP
19
1
4
CYS
SEE REMARK 999
SER
19
2LY0
D
Q6XT21
UNP
19
1
BINDING SITE FOR RESIDUE A2Y A 100
A
A2Y
100
Software
5
A
VAL
27
A
VAL
9
5
1_555
A
ALA
30
A
ALA
12
5
1_555
B
VAL
27
B
VAL
9
5
1_555
C
VAL
27
C
VAL
9
5
1_555
D
VAL
27
D
VAL
9
5
1_555